PUBLISHER: Grand View Research | PRODUCT CODE: 2112227
PUBLISHER: Grand View Research | PRODUCT CODE: 2112227
The global healthcare analytical testing services market size was valued at USD 17.0 billion in 2025 and is projected to grow from USD 18.4 billion in 2026 to USD 32.7 billion by 2033, at a CAGR of 8.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 39.2% in 2025. The healthcare analytical testing services industry is experiencing sustained growth driven by increasing pharmaceutical and biotechnology research activities, expanding biologics and biosimilars pipelines, rising outsourcing of analytical testing services, stringent global regulatory requirements, and continuous advancements in analytical technologies.
Growing investments in cell and gene therapies, antibody drug conjugates, RNA therapeutics, and personalized medicines are further increasing demand for specialized analytical capabilities across the product development lifecycle. Pharmaceutical companies are seeking faster development timelines while maintaining regulatory compliance, leading to greater adoption of outsourced testing services that offer advanced instrumentation and scientific expertise. One of the primary growth factors is the rapid expansion of biologics and other complex therapeutics. Biologics require extensive characterization, impurity profiling, stability assessment, bioanalytical studies, and comparability testing before regulatory approval.
Such products involve sophisticated molecular structures and greater manufacturing variability than conventional small-molecule drugs, creating demand for highly specialized analytical laboratories equipped with advanced chromatography, mass spectrometry, spectroscopy, and molecular biology platforms. For instance, in October 2025, Eurofins Viracor BioPharma Services commenced operations at a renovated 8,800 m2 laboratory in Lenexa, Kansas, expanding specialty bioanalytical and biomarker testing capabilities for infectious diseases, oncology, autoimmune disorders, cell and gene therapies, and biologics, while adding LCMS bioanalytical capacity for both large and small molecule drug development.
In addition, the increasing outsourcing of analytical testing by pharmaceutical, biotechnology, and medical device manufacturers. Many companies prefer external analytical laboratories to gain access to specialized expertise, validated analytical methods, regulatory knowledge, and advanced instrumentation without making substantial capital investments. Outsourcing also enables manufacturers to optimize operational costs, improve laboratory efficiency, and accelerate regulatory submissions while focusing internal resources on drug discovery and manufacturing activities. The growing number of virtual biotechnology companies and small biopharmaceutical firms with limited in-house analytical infrastructure continues to strengthen demand for contract analytical testing providers across preclinical, clinical, and commercial development stages.
Global Healthcare Analytical Testing Services Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare analytical testing services market report based on type and region: